Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 sham-controlled study of intravitreal aflibercept for macular edema secondary to central retinal vein occlusion
2009-010973-19Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in central retinal vein occlusion (CRVO) and macular edema (2 arms), sponsored by Bayer. Primary endpoint: Proportion of subjects gaining at least 15 letters in best-corrected visual acuity. Started Jul 2009; status: completed.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion (CRVO)macular edema
Beyond the preview
Go deeper on 2009-010973-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010973-19.